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Biofluidsa b s t r a c t
NMR is widely applied in the field of metabolomics due to the quantitative nature of the technology and
the reproducible data generated. However, because of severe spectral crowding, quantifying individual
metabolites in body fluids such as serum and plasma remains a challenge. In this study, a method to
automatically annotate and quantify a number of small metabolites in human serum and EDTA plasma is
introduced. It combines the superior signal-to-noise ratio of the commonly applied CPMG and NOESY1D
pulse sequences with the superior resolution of the 2D JRES experiment to construct a model that ex-
tracts the metabolite concentrations directly from the 1D spectra without tedious deconvolution. The
performance of the method was assessed by comparing the calculated areas of the various glucose peaks
with known clinical values, by comparing several peaks of the same metabolite (extracted versus non-
extracted), and by comparing areas obtained from various NMR pulse sequences. Additionally, the
models were tested on independent datasets. It was found that for many metabolites peaks could be
assigned that show a consistent behavior, indicating a precise quantification. The same method should be
applicable to other biofluids with a stable composition and pH, such as CSF fluid, cell extracts, and cell
media.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nuclear magnetic resonance (NMR) is one of the major analyt-
ical techniques employed in the field of metabolomics [1] [2] [3] [4]mail.com (A. Verhoeven).
B.V. This is an open access article u[5] [6]. While NMR cannot match the sensitivity of the mass
spectrometric techniques, it offers, however, superior reproduc-
ibility and facile quantitation, based on a linear relation between
the peak area and the concentration of the corresponding analyte
[7] [8] [9] [10]. However, analyte quantitation by NMR may be
complicated by “spectral crowding” which relates to overlapping
signals of different compounds due to the limited chemical shift
dispersion relative to the linewidth. The phenomenon is oftennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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spectra which are routinely acquired in NMRmetabolomics studies
of plasma and serum [11]. This situation is exacerbated by the fact
that most metabolites show multiple peaks at various locations in
the spectrum, and that these peaks are often split into multiplets
due to J-coupling [12]. These multiplets form complex patterns,
particularly when multiple couplings exist. In the past, several
groups have demonstrated that it is possible to simulate and sub-
sequently fit the multiplets of a severely overlapped NMR spectrum
[13] [14] [15] [16] [17]. None of the available fitting algorithms,
however, guarantees optimal convergence, as there is always a risk
of sliding into a local minimum and consequently a need for a
human intervention. Alternatively, one can use one of the many
available NMR pulse sequences to separate the different in-
teractions in a nuclear spin system. For example, in the J-resolved
2D experiment (JRES) [18], the peak splitting caused by the J-cou-
plings and the chemical shift are separated into different di-
mensions, significantly reducing the peak overlap problems [19].
The gain in the resolution comes at a cost, as 2D experiments take
significantly longer to record than 1D spectra, reducing the prac-
tically achievable signal-to-noise ratio.
Thus, metabolite quantification in complex samples remains a
cumbersome task demanding either extensive spectrometer time
when using JRES experiments, or researcher's time invested into a
meticulous validation of the simulation and fitting algorithms. Here
we demonstrate a way to overcome these limitations: we build a
numerical model from a set of JRES spectra and their corresponding
1D spectra, and thenwe apply the model directly to the 1D spectra,
extracting the surface area of the individual metabolite peaks. Us-
ing this approach, we save valuable spectrometer time by not
recording a time-consuming JRES spectrum for future cohorts, and
quickly extract peak areas from the 1D spectra without tedious
deconvolution. The construction of this model exploits the reso-
lution of the JRES spectrum and uses the integrals thus obtained to
extract identical information from the 1D spectra, in which the
peaks are less well resolved but have a better signal to noise ratio.
Moreover, all the peaks included in the model are annotated using
the combined information from chemical shift databases, spiking
experiments, and correlation behaviors. We also demonstrate that
the serum- and plasma-based models produce similar results and
compare the results to “classic” clinical chemistry results. Finally,
we test the plasma and serum models on independent datasets.Fig. 1. Flow chart for the construction of the metabolite quantification method. This
procedure was followed for serum and plasma separately.2. Materials and methods
2.1. Chemicals
If not stated otherwise all chemical were of p.a. or LC-MS grade
and were obtained from Sigma Aldrich (Schnelldorf, Germany).2.2. Cohorts
For the training of the EDTA plasma model, 3189 spectra of
samples from the Netherlands Twin Registry (NTR) [20], 46 spectra
from QC samples consisting of plasma from one of the authors, and
3545 spectra from the Leiden Longevity Study (LLS) [21] cohorts
were used. This model was validated using 673 spectra from the
Cardiovascular Registry Maastricht (CAREMA) [22] cohort. For the
training of the serum model, 1624 spectra from the Erasmus Ruc-
phen Family (ERF) [23] and 2181 spectra from the MARK-AGE [24]
cohorts were used. The serum model was validated using the 55
spectra from the cohort from the work by Bakker et al., which for
the purposes of this article will be named HDL functionality (HDLF)
[25] cohort.2.3. NMR measurements
All proton nuclear magnetic resonance (1H-NMR) experiments
were acquired on a 600MHz Bruker Avance II spectrometer (Bruker
BioSpin, Karlsruhe, Germany) equipped with a 5-mm triple reso-
nance inverse (TCI) cryogenic probe head with Z-gradient system
and automatic tuning and matching. The spectrometer is part of a
Bruker metabolic profiler platform, which also includes two Gilson
liquid handler robots. All experiments were recorded at 310 K.
Temperature calibration was done before each batch of measure-
ments using the method of Findeisen et al. [26]. The duration of the
p/2 pulses were automatically calibrated for each individual sample
using a homonuclear-gated nutation experiment on the locked and
shimmed samples after automatic tuning and matching of the
probe head.
EDTA plasma and serum samples were thawed at 4 C and were
mixed by inverting the tubes 10 times. Next, samples (300 ml) were
Fig. 2. An example of a JRES spectrum, where the area where one of the peaks in the
multiplet of glutamine is likely to appear is indicated by a blue square. The location of
maximum intensity within this square is determined, and the area around this posi-
tion, indicated by the red square, is integrated. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3. A schematic representation of the strategy to find the optimal area for con-
structing the models, using leucine and isoleucine as examples. From the position of
the peak in the indirect dimension, three different centers of the section in the 1D
spectrum that will be used for the model construction are derived. The three sections
refer to different parts of the multiplet in the 1D spectrum. One of these sections is
likely to have less interference from other metabolites than the others. The width of
the section is also optimized.
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(80/20) with a pH of 7.4 containing 6.15 mM NaN3 and 4.64 mM
sodium 3-[trimethylsilyl] d4-propionate using a Gilson 215 liquid
handler in combination with a Bruker SampleTrack system. Sam-
ples were transferred into 5-mm SampleJet NMR tubes in 96 tube
racks using a modified Gilson 215 tube filling station and kept at
6 C on a SampleJet sample changer while queued for acquisition.
For water suppression, presaturation of the water resonance with
an effective field of gB1 ¼ 25 Hz was applied during the relaxation
delay.
A 1D-version of the NOESY experiment was performed with a
relaxation delay of 4 s. A NOESY mixing time of 10 ms was used
during which the water resonance was irradiated with the pre-
saturation RF field. After applying 4 dummy scans, a total of 98,304
data points covering a spectral width of 18,029 Hz were collected
using 16 scans.
For T2-filtered 1H NMR spectra, a standard 1D Carr-Purcell-
Meiboom-Gill (CPMG) pulse sequence was used with a relaxation
delay of 4 s. A pulse train of 128 refocusing pulses with individual
spin echo delays of 0.6 ms was applied resulting in a total T2
filtering delay of 78 ms. After applying 4 dummy scans, a total of
73,728 data points covering a spectral width of 12,019 Hz were
collected using 16 scans.
For both 1D spectra, the Free Induction Decay (FID) was zero-
filled to 131,072 complex data points, and an exponential window
function was applied with a line broadening factor of 1.0 Hz before
Fourier transformation. The spectra were automatically phased and
baseline corrected.
J-resolved spectra (JRES) were recorded with a relaxation delay
of 2 s and a total of 1 scan for each increment in the indirect
dimension. A data matrix of 40  12,288 data points was collected
covering a sweep width of 78  10,000 Hz. A sine-shaped window
functionwas applied, and the data were zero-filled to 256  16,384
complex data points before Fourier transformation. The resulting
data matrix was tilted along the rows by shifting each row (k) by
0.4992 * (128 - k) points and symmetrized about the central hori-
zontal lines to compensate for the skew of the multiplets in the F1
dimension. All spectra underwent a quality check before enteringthe processing pipeline, consisting primarily of a check of the
alanine linewidth, the area of the water peak, and the phase of the
reference peak. Spectra that failed the quality control parameters
were excluded, most importantly those for which the alanine
linewidth exceeded 1.2 ppm.
The spectra were subsequently imported into Matlab (R2012b,
The Mathworks Inc, Natick, MA, USA) using an in-house written
code. The JRES spectrum was calibrated with respect to the
weighted average position of the anomeric glucose peak, which
was set to 5.23 ppm. The average intensity of the area
between 2.5 ppm and 1.0 ppm in the direct dimension, and
0.025 and 0.050 ppm in the indirect dimension was subtracted
from the whole spectrum as a baseline correction. For the CPMG
and NOESY1D spectra, the average of the spectral intensity up-field
from 3 ppm and downfield from 12.5 ppm was subtracted from
the spectra as a simple baseline correction. The spectra were
automatically calibrated with respect to the resonance of the
anomeric glucose proton which was set to 5.23 ppm. In order to
exactly line up the sampling points of the chemical shift axes of the
different spectra, they were resampled using spline interpolation,
generating 124347 points between 5 and 14 ppm. Subsequently
the points were binned by taking the average over sections with a
width of 0.002 ppm.2.4. Preparation of spiked samples
Standard material for sample fortification was accurately
weighed before addition. The full list of spiking materials, the
amounts weighed and the volumes for liquid materials are given in
the supplementary information. The materials were dissolved in
the standard buffer that is used for preparing plasma and serum
Fig. 4. The CPMG model intensities of the mixed serum samples spiked with various metabolites. The spiked metabolites are on the vertical axis, while the NMR-derived intensities
are on the horizontal axis. The values are normalized row-wise, for easy comparison of the intensity of a spiked sample with non-spiked samples.
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material was not dissolvable in buffer, regular milliQ water was
used instead. In a few cases this was not sufficient, and droplets of
hydrochloric acid were slowly added until the spiking compounds
were dissolved. The thus-prepared solutions were diluted with
buffer to yield the working solution. To obtain the mixture of
serum/plasma for the measurements, 20 ml of working solutionwas
mixed with 280 ml of buffer and 300 ml of plasma/serum.Fig. 5. Pearson correlation of the various glucose peak areas in the ERF cohort with the clinic
of the values generated by the CPMG and NOESY1D models, respectively, while the blue bars
to colour in this figure legend, the reader is referred to the web version of this article.)3. Results and discussion
3.1. Strategy
The flowchart in Fig. 1 provides an outline of our strategy: a
computational model is built on a set of training cohorts using both
JRES and 1D data; the model can subsequently be used for quan-
tifying metabolites in a new study using only the 1D spectra. Theal glucose levels in the ERF dataset. The red and the green bars indicate the correlations
show the correlations of the JRES peaks integrals. (For interpretation of the references
Table 1
The final list of serum metabolites that can be quantified using the method described in this paper, and the IDs and JRES chemical shifts of the best peaks representing these





















S009 0.873 0.98 1.00 0.97 1.00 1.00 1.00 0.87 Lipids (CH3)
S011 0.891 0.83 0.98 0.94 0.99 0.75 0.97 0.98 2-Hydroxybutyrate
S019 0.946 0.98 0.97 0.96 0.94 0.90 0.99 0.92 Leucine
S024 1.000 0.98 0.97 0.97 0.96 0.98 0.98 0.98 Isoleucine
S025 1.032 0.96 0.96 0.96 0.98 0.99 0.99 0.99 Valine
S027 1.063 0.87 0.93 0.78 0.91 0.93 0.92 0.96 3-
Hydroxyisobutyrate
S030 1.112 0.84 0.90 0.81 0.91 0.67 0.80 0.39 Alpha-
ketoisovalerate
S034 1.175 1.00 1.00 1.00 0.98 0.92 0.93 0.51 Ethanol
S037 1.191 1.00 1.00 0.99 0.99 1.00 1.00 0.99 3-Hydroxybutyrate
S043 1.266 0.98 1.00 0.90 1.00 1.00 1.00 0.81 Lipids (CH2)
S053 1.471 0.96 0.97 0.96 0.93 0.99 1.00 0.96 Alanine
S063 1.909 1.00 1.00 1.00 0.99 0.99 1.00 0.85 Acetate
S087 2.132 0.92 0.94 0.88 0.91 0.88 0.91 0.57 Methionine
S091 2.221 0.95 0.99 1.00 1.00 0.93 0.99 0.96 Acetone
S092 2.222 0.98 0.99 0.95 0.99 0.99 1.00 0.89 Lipids (CH2CO)
S104 2.350 0.96 0.96 0.98 0.91 0.92 0.96 0.94 Glutamate
S107 2.363 1.00 0.99 0.99 0.93 1.00 1.00 0.14 Pyruvate/Oxal.
S111 2.394 0.75 0.88 0.71 0.86 0.26 0.56 0.84 Succinate
S112 2.413 0.46 0.87 0.58 0.87 0.37 0.76 0.91 Carnitine
S119 2.463 0.70 0.97 0.72 0.97 0.67 0.96 0.87 Glutamine
S122 2.528 0.97 0.98 0.97 0.98 0.96 0.98 0.66 Citrate
S128 2.719 0.56 0.73 0.73 0.83 0.01 0.44 0.71 DMA
S141 2.916 0.80 0.91 0.85 0.90 0.72 0.69 0.82 Dimethylglycine
S146 2.994 0.63 0.81 0.88 0.88 0.42 0.75 0.14 Alpha-
ketoglutarate
S148 3.023 0.90 0.92 0.91 0.93 0.85 0.95 0.93 Lysine
S151 3.050 0.83 0.83 0.93 0.92 0.62 0.83 0.82 Ornithine
S162 3.254 0.96 0.96 0.97 0.98 0.96 0.96 0.97 TMAO/Betaine
S163 3.268 0.96 0.98 0.96 0.98 0.97 0.98 0.97 1,5-
Anhydrosorbitol
S173 3.356 0.99 1.00 1.00 1.00 0.94 0.98 0.87 Methanol
S184 3.552 0.92 0.97 0.95 0.97 0.97 0.99 0.93 Glycine
S186 3.560 0.94 0.96 0.97 0.98 0.92 0.94 0.91 Glycerol
S191 3.623 0.78 0.91 0.75 0.89 0.59 0.83 0.64 Myoinositol
S218 3.883 0.77 0.98 0.59 0.97 0.69 0.94 0.98 Betaine
S221 3.920 0.99 0.98 0.99 0.99 0.98 0.99 0.98 Creatine
S233 4.045 0.94 0.95 0.95 0.97 0.79 0.95 0.94 Creatinine
S235 4.104 0.99 0.99 0.99 0.93 0.99 0.99 0.73 Lactate
S237 4.122 0.91 0.98 0.93 0.98 0.84 0.96 0.97 Proline
S245 5.230 1.00 1.00 0.99 1.00 0.98 1.00 0.95 Glucose
S246 5.297 0.97 0.99 0.96 0.99 0.98 0.99 0.85 Lipids
(CH¼CH*CH2)
S249 6.890 0.84 0.92 0.86 0.92 0.77 0.92 0.92 Tyrosine
S254 7.420 0.47 0.90 0.53 0.85 0.24 0.77 0.47 Phenylalanine
S256 8.451 0.89 0.96 0.85 0.95 0.31 0.26 0.25 Formate
A. Verhoeven et al. / Analytica Chimica Acta 976 (2017) 52e6256computational model is trained on a set of CPMG, NOESY1D and
JRES serum and plasma spectra that is assumed to be sufficiently
close to a random selection of serum and plasma samples from the
general population. Using a training set consisting of plasma and
serum samples we identify areas in the JRES 2D spectra where a
peak is expected and extract the integrals of this peak. Then, a
model that predicts the JRES integrals from the NOESY1D and
CPMG 1D spectra is created. A tentative peak assignment is given
on basis of the chemical shift andmultiplicities. For the metabolites
with multiple peaks, the peak that gives the best model is selected.
Peaks for which the model performance is not satisfactory are
discarded. Below, all the steps are discussed in detail.3.2. Integration of peaks in the JRES spectrum
The JRES spectra were imported into Matlab using in-housewritten code. Individual peaks in the 2D JRES spectra were inte-
grated and the values were used as a measure of the concentration
of the corresponding metabolites. For every peak, two parameters
were defined: the regionwhere the peak is likely to be located, and
the dimensions of the integration area. In order to identify the
spectral areas where each individual peak is located 200 spectra
were randomly selected, log-transformed and summed. By visual-
izing the resulting dataset as a contour plot, the spectral areas
covered by each peak could be identified and catalogued. For every
spectrum, the integration area of a peak was defined around its
“center point”, which was chosen by one of the following methods:
i) the middle of the peak area, ii) the center of mass of the peak
shape, or iii) the location of the peak maximum. For most small
metabolites the third method was used, while the second method
was mostly used for the lipoprotein peaks. The first method was
only used for a very complex JRES glutamine peak. In total this peak
Table 2
The final list of plasma metabolites that can be quantified using the method described in this paper, and the IDs and JRES chemical shifts of the best peaks representing these





















P009 0.873 0.96 0.99 0.97 1.00 0.98 0.99 0.87 Lipids (CH3)
P011 0.892 0.86 0.97 0.87 0.97 0.71 0.94 0.98 2-Hydroxybutyrate
P019 0.947 0.98 1.00 0.85 0.99 0.97 0.96 0.92 Leucine
P024 1.001 0.99 1.00 0.92 0.99 0.69 0.98 0.98 Isoleucine
P025 1.033 0.98 0.99 0.92 0.99 0.86 0.97 0.99 Valine
P027 1.064 0.93 0.96 0.86 1.00 0.92 0.94 0.96 3-
Hydroxyisobutyrate
P030 1.113 0.73 0.87 0.56 0.78 0.87 0.95 0.39 Alpha-
ketoisovalerate
P034 1.176 1.00 1.00 1.00 1.00 1.00 0.98 0.51 Ethanol
P037 1.192 1.00 0.98 0.94 0.98 1.00 0.99 0.99 3-Hydroxybutyrate
P043 1.265 0.90 0.98 0.78 0.94 0.96 0.97 0.81 Lipids (CH2)
P053 1.473 0.95 0.99 0.93 0.99 0.91 0.94 0.96 Alanine
P063 1.910 1.00 1.00 0.97 1.00 1.00 0.95 0.85 Acetate
P087 2.133 0.87 0.98 0.95 0.98 0.95 0.99 0.57 Methionine
P091 2.221 0.97 0.99 0.98 1.00 0.89 0.99 0.96 Acetone
P092 2.222 0.95 0.99 0.84 0.98 0.95 0.99 0.89 Lipids (CH2CO)
P104 2.350 0.98 0.99 0.96 1.00 0.92 0.99 0.94 Glutamate
P107 2.364 0.98 1.00 0.22 0.87 0.97 0.99 0.14 Pyruvate/Oxal.
P111 2.395 0.59 0.85 0.91 0.97 0.97 0.98 0.84 Succinate
P113 2.413 0.44 0.93 0.46 0.91 0.42 0.90 0.91 Carnitine
P120 2.465 0.71 0.95 0.75 0.91 0.93 0.78 0.87 Glutamine
P122 2.532 0.94 0.99 0.88 0.99 0.79 0.96 0.66 Citrate
P123 2.556 0.70 0.97 0.57 0.98 0.97 0.99 Ca-EDTA
P128 2.697 0.83 0.97 0.77 0.99 0.97 0.98 Mg-EDTA
P129 2.720 0.78 0.92 0.85 0.95 0.99 0.99 0.71 DMA
P142 2.918 0.95 0.98 0.87 0.93 0.82 0.97 0.82 Dimethylglycine
P147 2.995 0.47 0.83 0.05 0.29 0.33 0.75 0.14 Alpha-
ketoglutarate
P149 3.024 0.92 0.98 0.83 0.97 0.83 0.97 0.93 Lysine
P152 3.052 0.87 0.96 0.47 0.94 0.46 0.96 0.82 Ornithine
P160 3.255 0.97 0.99 0.97 0.99 0.96 0.98 0.97 TMAO/Betaine
P161 3.269 0.95 0.98 0.91 0.98 0.93 0.97 0.97 1,5-
Anhydrosorbitol
P163 3.279 0.80 0.95 0.68 0.87 0.47 0.68 0.64 Myoinositol
P171 3.356 1.00 1.00 0.99 1.00 0.95 0.98 0.87 Methanol
P181 3.554 0.97 0.99 0.90 0.98 0.28 0.97 0.93 Glycine
P182 3.561 0.84 0.97 0.68 0.95 0.05 0.82 0.91 Glycerol
P212 3.882 0.67 0.97 0.52 0.97 0.79 0.94 0.98 Betaine
P215 3.921 0.99 1.00 0.98 1.00 0.97 0.99 0.98 Creatine
P227 4.045 0.96 0.99 0.95 0.99 0.80 0.96 0.94 Creatinine
P229 4.104 0.99 1.00 0.97 1.00 0.99 0.99 0.73 Lactate
P231 4.123 0.95 0.99 0.90 0.98 0.87 0.93 0.97 Proline
P239 5.231 1.00 1.00 0.97 1.00 1.00 1.00 0.95 Glucose
P240 5.297 0.91 0.98 0.81 0.97 0.92 0.97 0.85 Lipids
(CH¼CH*CH2)
P243 6.892 0.94 0.97 0.79 0.87 0.82 0.81 0.92 Tyrosine
P248 7.422 0.55 0.90 0.29 0.79 0.35 0.92 0.47 Phenylalanine
P250 8.452 0.88 0.96 0.95 0.99 0.98 0.99 0.25 Formate
A. Verhoeven et al. / Analytica Chimica Acta 976 (2017) 52e62 57selection and integration process yielded 250 integrals per JRES 2D
spectrum for EDTA plasma and 256 integrals for serum. In Fig. 2 an
example is shown where one of the peaks of the complex gluta-
mine JRES pattern is first located, and subsequently integrated.
3.3. Constructing the model
The 1D data containing the processed spectral intensities from
the NOESY1D and CPMG spectra and the peak integrals from the
JRES spectra were subsequently used to build a linear model that
predicts the JRES integrals from the 1D data. For every JRES peak
integral, the corresponding 1D spectrumwas used to build a linear
model using the robust regression function in the statistics toolbox
of Matlab. We used the default settings (bisquare weight function,
tuning factor 4.685), a detailed description of the function is givenhere: https://nl.mathworks.com/help/stats/robustfit.html. Using
the whole 1D spectrum to predict the intensity of a single peak in
the JRES spectrum would however lead to the inclusion many
variables that are unrelated to the concentration of the corre-
sponding metabolite and would most likely lead to severe over-
fitting. Therefore, only a relatively small section of the 1D spectrum
around the chemical shift of the peak in the 2D spectrumwas used
to build the model. Taking the same section width for every peak
would be the simplest solution. Nevertheless, this does not take
into account the multiplicity of the peak, and the fact that the
spectral environments of various peaks can be vastly different.
Therefore, the position of the middle of the subsectionwith respect
to the center peak of the multiplet in the JRES spectrum and the
width of the sectionwere optimized. A schematic representation of
this optimization is shown in Fig. 3. The total width of the area was
Fig. 6. Pearson correlations between the JRES integrals and the CPMG values of the best-performing metabolite peaks for plasma (red) and serum (green). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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done for three different choices of the middle of the section. The
position of the peak in the JRES spectrum is determined by the two
values, and in the weak-coupling limit one of those (F2) is only
dependent on the chemical shift, while the other (F1) is determined
by the J-coupling. Since in the 1D spectrum both interactions
contribute to the position of a peak in a multiplet, they were both
used for determining the center of the section used for the linear
model. F2, F2-F1 and F2þF1 were all attempted as the center of the
section. All these different section widths and positions were used
to build linear models for predicting the JRES peak integrals from
the 1D data. The best model was selected by doing a 10-fold cross-
validation for every option. This process was repeated for every
peak in the JRES 2D spectrum separately.
3.4. Metabolite identification
The annotation of the selected peaks consisted of several steps.
First, the online databases such as Human Metabolome Database
(HMDB) [27] and Biological Magnetic Resonance Bank (BMRB) [28]
were used to find likely metabolite assignments for each peak.
Then, the spectra themselves provided chemical shift and multi-
plicity information that were used to assemble a list of possible
assignments andmatch it to the values reported in the publications
on serum and plasma metabolomics [29] [30] [31] [32] [33] [34]
[35] [36] [37]. In some cases this was sufficient to assign a peak
to a specific compound, but in other cases there were two or more
candidate metabolites. However, it can be expected that the various
proton signals derived from a specific metabolite show strong
correlation patterns. Hence, akin to the STOCSY approach for theanalysis of metabolomics data, a peak could be assigned with high
reliability when it showed the correlations that were expected from
a specific metabolite. Fig. S4 shows an example for the high-field
region of the spectrum.
To confirm the assignment analytical standards of the metabo-
lites were added to serum and plasma samples. CPMG, NOESY1D
and JRES spectrawere recorded according the standard protocol. By
visually comparing the spectra of the spiked samples with that of a
blankmixture, the assignments could be verified. Subsequently, the
computational models were applied to the spiked spectra to eval-
uate the model behavior. Fig. 4 gives a graphical representation of
the model response. With some exceptions, the results indicated
that the computational model for a metabolite only responded to
that specific one, and not significantly to others. Pyruvate and
oxaloacetate could not be individually quantified because the
chemical shifts of the two compounds are too similar. The model
therefore generated a value that represents both metabolites. The
samewas true for betaine and TMAO. The analysis also showed that
spiking with alpha-ketoglutarate caused the model for glutamine
to produce unrealistic values. This did not happen the other way
around. This is unlikely to be a problem in real-life applications, as
the concentration of alpha-ketoglutarate in serum is much lower
than that of glutamine, making cross-talk unlikely.
3.5. Model reliability
All identifiable peaks in the JRES 2D spectrumwere used to build
linear models that predict the integrals of those peaks from the
NOESY1D and CPMG spectra. However, a correct estimation of the
concentration of the corresponding metabolite is not given by all
Fig. 7. Scatter plots showing the correlation between different metabolite quantifications for one of the serum training cohorts in blue (ERF) and a validation cohort in red (HDLF). A
and C: scatter plots showing the correlation of the JRES integrals (x-axis) versus the CPMG values for peak 245/glucose (A) and peak 237/proline (C). B and D: the correlation
between the CPMG values from peaks at different locations in the spectrum, for peaks 208 and 245 of glucose (B) and peaks 169 and 237 of proline (D). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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in the 1D spectrum caused by other metabolites. In other cases
differences in pH or ionic strength happened to create peak shifts
rendering construction of a simple linear model impossible. Thus, a
simple metrics was needed which would give an estimate of
model's reliability. An empirical selection of the possibilities
showed that the most obvious one was the correlation between the
actual JRES integral and the JRES integral as predicted from the
NOESY1D and CPMG spectra. The correlations are given in Tables S1
and S2 of the supporting information. Since the JRES spectrum had
a lower signal-to-noise ratio than the 1D spectra, the correlation of
the 1D data with the actual metabolite concentrations may actually
be higher than the correlation between the 1D data and the 2D
data. In Fig. 5A, the correlation between glucose levels as deter-
mined by NMR and by the standard hexokinase-glucose-6-
phosphate dehydrogenase method are shown [38]. Although
peaks that correlate well with the clinical glucose concentration
were found for all three different NMR pulse sequences, some
peaks showed a better correlation for the 1D models than for the
JRES integrals. It is notable that for some glucose peaks, for exampleS202, the values generated by the model showed a better correla-
tionwith the clinical glucose concentration than the training values
for those models. Therefore the CPMG and the NOESY1D experi-
ments seemed more robust, as a larger number of glucose peaks
achieved a high correlation. This is also illustrated by the fact that
the correlation between the CPMG and the NOESY1D data was
often higher than the correlation between the JRES spectrum and
the CPMG/NOESY1D spectra. Therefore, a model with a relatively
low 1D-2D correlation may still be useful if the correlation between
the values extracted from the two 1D spectra is high. This could be
confirmed for instances where the corresponding metabolite had
more than one resonance in the spectrum; a high correlation be-
tween different peaks from the same metabolite was found to be a
good indication of a reliable model. For example, the Pearson cor-
relation between JRES and CPMG was found to be 0.71 for the
glutamine peak P120 in the LLS cohort, but the correlation between
the CPMG value of this peak and that of another glutamine peak
(P89) was 0.87, indicating a good model. Of the multiple peaks, the
one with the best correlation properties was selected for further
processing. This selection of assigned JRES peaks with optimal
Fig. 8. Correlations between the serum and plasma levels of the best-performing metabolite peaks. Given are the correlations between the values of the CPMG (red) and the
NOESY1D (green) serum and plasma models, and the JRES peak integrals. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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Pearson correlation between the JRES integrals and the CPMG
model values for these peaks is given in Fig. 6.
3.6. Validation on independent cohorts
In order to validate our model on a set of independent obser-
vations we took advantage of the data obtained from the HDLF and
the CAREMA cohorts for the serum and plasma models, respec-
tively. A first measure of the model performance is the correlation
between the JRES and the CPMG experiments. A better test can be
defined by the fact that many metabolites generate multiple peaks
at different locations in the spectrum and hence can be used to test
the model, since the correlation between these peaks should
theoretically be close to 1. Fig. 7 shows the quantification of a high-
concentration metabolite (glucose) and a lower concentration
metabolite (proline) in the training cohorts and the validation co-
horts. In these examples the validation cohorts clearly behave
similar to the training cohorts. Fig. S1 shows two other examples
for plasma. Proline was chosen as an example for validation owing
to its relatively low concentration and its complex coupling pattern
generating several peaks in the JRES spectrum. Fig. S2 shows the
correlation of the proline levels as determined from the CPMG and
the NOESY1D experiments with those of the JRES experiment, and
of the mutual correlation of the two 1D experiments. For the LLS
cohort, which was one of the cohorts used to construct the model,
the correlations of the 1D values with the JRES are somewhat
higher than for CAREMA, which we used as a validation cohort. This
is partly caused by the lower dispersion of the proline concentra-
tions in the CAREMA cohort. Nevertheless, some peaks still have a
high correlation between the CPMG values and the JRES integrals of
r> 0.8, and themutual correlation of the two 1D experiments is still
very good in the independent cohort. In addition to selection of the
well modelled peaks, these findings are also applicable to defining
the most adequate NMR signals for quantification in case of the
metabolites generating multiple peaks.Hence, the high correlations in the LLS and the NTR training
cohorts, caused us to select peak S231 as the best peak for proline
quantification. In LLS, the correlation of this peak with most other
proline peaks in the CPMG spectrum is higher than 0.9, while in
CAREMA (the validation cohort) this is reduced to 0.8. Also here the
superior correlation of all the proline peaks in the 1D spectra with
the highest-performing peak as compared to the correlations of the
JRES integral is notable. Fig. S3 shows similar behavior for the peaks
of 1,5-anhydrosorbitol, where peak S161 was selected as the best-
performing peak. On average for plasma, the Pearson correlation
coefficient between the CPMG model values and the JRES integrals
is 0.055 lower in the training cohort than in the validation cohort.
Considering that two different models were generated for
serum and plasma, another good test of these models would be a
comparison between the metabolite values determined from
plasma and serum samples taken from the same patient at the
same time-point. This was tested for the NTR cohort, where for
some participants both plasma and serum samples were available.
Essentially, a training cohort for the plasma model is compared to a
validation cohort for the serum model. These correlations are
shown in Fig. 8. Generally, the correlations are very good. There are
some exceptions that can be attributed to the age and the storage
conditions of the samples. For example, it is known that in samples
that are stored at30 C, glutamine is slowly oxidized to glutamate.
Also formate often reported to be a result of microbial activity
during storage [42].
4. Conclusions and perspectives
Here we present a computational model that can replace
cumbersome deconvolution approaches for the quantification of
metabolites in biofluids with a stable composition and pH, in this
case serum and EDTA plasma. The model was constructed using the
JRES 2D spectrum, the NOESY1D spectrum and the CPMG spectrum
simultaneously. Using the data obtained from the HDLF and the
CAREMA cohorts we have shown that if properly trained and
A. Verhoeven et al. / Analytica Chimica Acta 976 (2017) 52e62 61optimized, the model is sufficiently robust to be applied to new
data. To use our model one needs only the CPMG or the NOESY1D
data, which reduces significantly the data acquisition time, giving
an important advantage in the large scale clinical metabolomics
studies. Yet, in practice, performing JRES measurements on a few
randomly selected samples is advisable for the purpose of quality
control. Similar models could be constructed for other biofluids, for
example synovial fluid, intracellular metabolites or cerebrospinal
fluid (CSF). An obvious direction for the further method develop-
ment is the absolute quantitation which could be achieved by
including the protocols using either a real or an artificial (ERETIC)
reference signal. The reference compound could be included into
the model: by varying the concentration of the reference com-
pound in the training set, the model can be trained to extract the
JRES reference compound integral from the 1D spectra, allowing
quantification of the other signals. However, the strong coupling
effects may complicate the model building process, not to mention
that finding an ideal reference compound is a problem by itself [39]
[40] [41]. There is certainly more than one way of addressing the
method extension towards absolute quantitation. An important
point is that the method present here provides a solid fundament
for such extensions, which can be tailored by a user to optimally fit
his/her applications.
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